Abstract


 CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class.
 The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec.
 This review assesses ibrutinib (Imbruvica) 140 mg capsule, oral.
 Indication: Ibrutinib in combination with venetoclax for the treatment of adult patients with previously untreated chronic lymphocytic leukemia, including those with 17p deletion.

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call